Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration

Purpose. To study long-term clinical outcomes in patients with submacular hemorrhage (SMH) and/or vitreous hemorrhage (VH) associated with neovascular age-related macular degeneration (nAMD) and the real-world clinical situation of adding anti-VEGF therapy after pars plana vitrectomy (PPV). Methods....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Setsuko Kawakami, Yoshihiro Wakabayashi, Kazuhiko Umazume, Yoshihiko Usui, Daisuke Muramatsu, Tsuyoshi Agawa, Kaori Yamamoto, Hiroshi Goto
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f4237bd18d42464cbc45bd0feb942069
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f4237bd18d42464cbc45bd0feb942069
record_format	dspace
spelling	oai:doaj.org-article:f4237bd18d42464cbc45bd0feb9420692021-11-15T01:19:09ZLong-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration2090-005810.1155/2021/2963822https://doaj.org/article/f4237bd18d42464cbc45bd0feb9420692021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2963822https://doaj.org/toc/2090-0058Purpose. To study long-term clinical outcomes in patients with submacular hemorrhage (SMH) and/or vitreous hemorrhage (VH) associated with neovascular age-related macular degeneration (nAMD) and the real-world clinical situation of adding anti-VEGF therapy after pars plana vitrectomy (PPV). Methods. In this retrospective case series, 25 eyes with SMH and/or VH associated with nAMD were treated by PPV and followed up for at least 24 months. When exudative changes were unresolved or recurred after PPV, additional intravitreal anti-VEGF therapy was given. Results. The reasons for performing PPV were SMH (8 eyes) and VH (17 eyes) associated with nAMD. Mean best-corrected visual acuity (BCVA) of eyes with SMH improved significantly at 6 months (P<0.01) and 12 months (P<0.05) after PPV. Mean BCVA of eyes with VH improved at 1, 3, 6, 12, 18, and 24 months (P<0.01) and at the final visit (P<0.05). Post-PPV anti-VEGF therapy was initiated in 6 of 8 (75.0%) eyes with SMH and 7 of 17 (47.1%) eyes with VH. Of the 13 eyes given anti-VEGF therapy after PPV, 11 eyes had anti-VEGF therapy initiated within 10 months after surgery. Dry macula rate after PPV was 50.0% in SMH and 70.6% in VH. Conclusions. BCVA improved in eyes with SMH at 6 and 12 months after PPV, and the BCVA was maintained until the end of the study. BCVA improved significantly in eyes with VH at all time points after PPV. In eyes undergoing PPV for nAMD, recurrence of exudative changes after 11 months from the initial PPV was rare.Setsuko KawakamiYoshihiro WakabayashiKazuhiko UmazumeYoshihiko UsuiDaisuke MuramatsuTsuyoshi AgawaKaori YamamotoHiroshi GotoHindawi LimitedarticleOphthalmologyRE1-994ENJournal of Ophthalmology, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Setsuko Kawakami Yoshihiro Wakabayashi Kazuhiko Umazume Yoshihiko Usui Daisuke Muramatsu Tsuyoshi Agawa Kaori Yamamoto Hiroshi Goto Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
description	Purpose. To study long-term clinical outcomes in patients with submacular hemorrhage (SMH) and/or vitreous hemorrhage (VH) associated with neovascular age-related macular degeneration (nAMD) and the real-world clinical situation of adding anti-VEGF therapy after pars plana vitrectomy (PPV). Methods. In this retrospective case series, 25 eyes with SMH and/or VH associated with nAMD were treated by PPV and followed up for at least 24 months. When exudative changes were unresolved or recurred after PPV, additional intravitreal anti-VEGF therapy was given. Results. The reasons for performing PPV were SMH (8 eyes) and VH (17 eyes) associated with nAMD. Mean best-corrected visual acuity (BCVA) of eyes with SMH improved significantly at 6 months (P<0.01) and 12 months (P<0.05) after PPV. Mean BCVA of eyes with VH improved at 1, 3, 6, 12, 18, and 24 months (P<0.01) and at the final visit (P<0.05). Post-PPV anti-VEGF therapy was initiated in 6 of 8 (75.0%) eyes with SMH and 7 of 17 (47.1%) eyes with VH. Of the 13 eyes given anti-VEGF therapy after PPV, 11 eyes had anti-VEGF therapy initiated within 10 months after surgery. Dry macula rate after PPV was 50.0% in SMH and 70.6% in VH. Conclusions. BCVA improved in eyes with SMH at 6 and 12 months after PPV, and the BCVA was maintained until the end of the study. BCVA improved significantly in eyes with VH at all time points after PPV. In eyes undergoing PPV for nAMD, recurrence of exudative changes after 11 months from the initial PPV was rare.
format	article
author	Setsuko Kawakami Yoshihiro Wakabayashi Kazuhiko Umazume Yoshihiko Usui Daisuke Muramatsu Tsuyoshi Agawa Kaori Yamamoto Hiroshi Goto
author_facet	Setsuko Kawakami Yoshihiro Wakabayashi Kazuhiko Umazume Yoshihiko Usui Daisuke Muramatsu Tsuyoshi Agawa Kaori Yamamoto Hiroshi Goto
author_sort	Setsuko Kawakami
title	Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
title_short	Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
title_full	Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
title_fullStr	Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
title_full_unstemmed	Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
title_sort	long-term outcome of eyes with vitrectomy for submacular and/or vitreous hemorrhage in neovascular age-related macular degeneration
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/f4237bd18d42464cbc45bd0feb942069
work_keys_str_mv	AT setsukokawakami longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT yoshihirowakabayashi longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT kazuhikoumazume longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT yoshihikousui longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT daisukemuramatsu longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT tsuyoshiagawa longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT kaoriyamamoto longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration AT hiroshigoto longtermoutcomeofeyeswithvitrectomyforsubmacularandorvitreoushemorrhageinneovascularagerelatedmaculardegeneration
_version_	1718429020891119616

Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration

Ejemplares similares